Zacks Research Has Bullish Estimate for CVKD Q3 Earnings

by · The Markets Daily

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Free Report) – Research analysts at Zacks Research lifted their Q3 2026 earnings per share (EPS) estimates for Cadrenal Therapeutics in a note issued to investors on Monday, August 31st. Zacks Research analyst D. Bautz now expects that the company will post earnings per share of ($0.87) for the quarter, up from their prior forecast of ($1.12). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.22) per share. Zacks Research also issued estimates for Cadrenal Therapeutics’ Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.76) EPS, FY2027 earnings at ($2.21) EPS and FY2028 earnings at ($1.78) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.28.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen upgraded Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cadrenal Therapeutics has a consensus rating of “Hold” and a consensus price target of $13.00.

View Our Latest Report on CVKD

Cadrenal Therapeutics Price Performance

Shares of NASDAQ:CVKD opened at $1.33 on Thursday. The company has a market capitalization of $4.75 million, a price-to-earnings ratio of -0.27 and a beta of 1.82. The business’s 50-day moving average is $2.21 and its 200-day moving average is $4.36. Cadrenal Therapeutics has a 1 year low of $1.28 and a 1 year high of $14.64.

Insiders Place Their Bets

In other Cadrenal Therapeutics news, CEO Quang X. Pham sold 12,996 shares of Cadrenal Therapeutics stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $3.94, for a total transaction of $51,204.24. Following the completion of the transaction, the chief executive officer owned 136,381 shares in the company, valued at approximately $537,341.14. The trade was a 8.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have sold 76,699 shares of company stock valued at $282,050. 14.59% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cadrenal Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CVKD. JPMorgan Chase & Co. bought a new position in Cadrenal Therapeutics during the 3rd quarter valued at $103,000. Geode Capital Management LLC grew its stake in shares of Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Cadrenal Therapeutics in the third quarter valued at about $274,000. Finally, DRW Securities LLC purchased a new stake in shares of Cadrenal Therapeutics in the fourth quarter valued at about $171,000. 7.92% of the stock is owned by hedge funds and other institutional investors.

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

See Also